Danish pharmaceutical giant Novo Nordisk, which rode a wave of unprecedented success with its weight-loss drug Wegovy, has announced a global hiring freeze for non-critical roles. This signals a dramatic shift from rapid expansion to rigorous cost-cutting. Sales begin to slow and competition intensifies. Novo Nordisk’s hiring freeze is a significant turn for the company. The Wegovy Hiring Spree The…
Tag: Novo Nordisk
-
Ozempic and Mounjaro are reshaping South Africa’s health market
The landscape of weight management and diabetes treatment in South Africa is undergoing a dramatic transformation. This change is driven by the meteoric rise in popularity of a class of drugs known as GLP-1s, including Ozempic and Mounjaro. These medications, initially developed for Type 2 diabetes, have shown significant efficacy in promoting weight loss. As a result, there is unprecedented…
-
Pharmaceutical industry fights to shield drugs from tariffs
Pharmaceutical giants are actively lobbying the Trump administration and European Union officials to exclude medical goods from escalating trade disputes. They fear significant price increases and restricted patient access to essential medications. The industry’s concerns centre on the potential impact of tariffs on top-selling drugs like Novo Nordisk’s Wegovy for weight loss and Merck’s cancer immunotherapy Keytruda. In discussions with…
-
Competition Commission probes insulin price fixing
The Competition Commission in South Africa has launched a formal investigation into leading insulin manufacturers Novo Nordisk and Sanofi Aventis following serious allegations of anti-competitive conduct. The inquiry was initiated after health activists complained about Novo Nordisk’s decision to cease supplying human insulin pens to the country’s Health Department in 2024. This move has forced thousands of diabetic patients to…
-
A decade of transformation in obesity treatment
For long-time attendees of ObesityWeek, the 2024 conference in San Antonio felt markedly different. In the past, it was an intimate gathering of obesity specialists focused on research and clinical updates. However, as one physician noted, “There’s a lot more suits.” Wall Street has joined the event, drawn by the explosion of interest in the lucrative obesity treatment market. Since…
-
Medicines seized amidst surge in demand for Ozempic copies
New Zealand customs officials recently seized 14 injectable pens labelled as Fitaro and Orsema – semaglutide-based medications manufactured by Incepta Pharmaceuticals, a drugmaker from Bangladesh. These drugs, meant to provide an affordable alternative to Novo Nordisk’s Ozempic, underscore a surge in demand for lower-cost versions of the popular diabetes and weight loss medication. Ozempic and its anti-obesity counterpart, Wegovy, contain…
-
GLP-1 drugs increase healthcare costs for obese patients
GLP-1 drugs, such as Novo Nordisk’s Wegovy, have become popular for weight loss among US patients struggling with obesity. Despite significant weight-loss benefits, an analysis of US health insurance claims reveals that these medications may drive healthcare costs higher rather than reducing obesity-related expenses. According to data from Prime Therapeutics, a pharmacy benefits manager, US patients’ average annual medical expenses…
-
As competition heats up, Novo Nordisk’s share price declines
Danish pharmaceutical giant Novo Nordisk, renowned for its diabetes and weight loss drugs Ozempic and Wegovy, has experienced a significant share price drop of around 19% this month. This decline follows its market peak in June, driven by increasing competition from Eli Lilly, a key player in the same space. Eli Lilly has gained substantial momentum with its rival drugs,…